Article Text

Download PDFPDF
An update on LAMA/LABA combinations for COPD


The management of symptoms of chronic obstructive pulmonary disease (COPD) typically involves the use of inhaled long-acting bronchodilators. Previously, we have reviewed the long-acting muscarinic antagonists (LAMAs) ▼aclidinium,1 ▼glycopyrronium,2 tiotropium3 and ▼umeclidinium,4 and the long-acting beta2 agonists (LABAs) indacaterol,5 ▼olodaterol,6 and ▼vilanterol (in combination with fluticasone) in the management of COPD.7 Four fixed-dose combinations of a LAMA with a LABA are now available, all indicated as maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. Here, we provide a brief overview of the four combinations and consider the place of a LAMA/LABA in people with COPD and any factors that might help to choose between them.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.